💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Amlodipine

CHEMBL1491 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
30-50 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
408.9 g/mol
LogP
3.0
Phase
4

This calcium channel blocker relaxes the walls of blood vessels, making it easier for the heart to pump blood and lowering blood pressure. It is prescribed for hypertension and chest pain, and some research suggests potential roles in neurological and heart rhythm conditions.

น้ำหนักโมเลกุล

408.8800 g/mol

LogP

3.00

TPSA

99.90 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

Ovarian Cancer Cardiovascular Disease Chronic Obstructive Pulmonary Disease Alzheimer's Disease Generalized Anxiety Disorder Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Hyperlipidemia Obesity Type 2 Diabetes Hypertension Breast Cancer HIV/AIDS Hepatitis C Heart Failure Atrial Fibrillation

หมวดหมู่ยา

C — C - Cardiovascular System

กลไกการออกฤทธิ์

Dihydropyridine calcium channel blocker.

Pharmacokinetics (PK)

Half-Life 30-50 hours

Pharmacodynamics (PD)

กลไก

Dihydropyridine calcium channel blocker.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl

                

                

                
                

                    
InChI

                    
InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C20H25ClN2O5

                    

                    
                    

                        
HBD / HBA

                        
2 / 7

                    

                    
                    

                        
พันธะที่หมุนได้

                        
10

                    

                    
                    
                    

                        
อะตอมหนัก

                        
28

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            AGTR1 (Angiotensin II Type 1 Receptor)
                            Other
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            ADRB2 (Beta-2 Adrenergic Receptor)
                            Other
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Minor


                            
                                Amlodipine + Lisinopril
                            
                        

                        
                        
The combination of amlodipine and lisinopril provides complementary antihypertensive mechanisms and may cause additive hypotension, particularly with initial dosing.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Amlodipine + Atorvastatin
                            
                        

                        
                        
Amlodipine weakly inhibits CYP3A4-mediated atorvastatin metabolism, leading to a modest increase in atorvastatin exposure; the combination is generally used safely in clinical practice.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Amlodipine + Doxycycline
                            
                        

                        
                        
Doxycycline is reported to modestly inhibit CYP3A4, potentially increasing amlodipine plasma levels; the clinical consequence is minor given amlodipine's wide therapeutic index.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Amlodipine + Simvastatin
                            
                        

                        
                        
Amlodipine inhibits CYP3A4-mediated simvastatin metabolism, increasing simvastatin plasma concentrations and the risk of statin-associated myopathy and rhabdomyolysis.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Amlodipine + Cyclosporine
                            
                        

                        
                        
Cyclosporine inhibits CYP3A4-mediated amlodipine metabolism, increasing amlodipine plasma concentrations and the risk of pronounced vasodilation and peripheral edema.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
This calcium channel blocker relaxes the walls of blood vessels, making it easier for the heart to pump blood and lowering blood pressure. It is prescribed for hypertension and chest pain, and some research suggests potential roles in neurological and heart rhythm conditions.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Dihydropyridine calcium channel blocker.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Amlodipine: Half-life: 30-50 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Amlodipine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Atorvastatin
                            Small molecule
                        
                        
                        
                            Lisinopril
                            Small molecule
                        
                        
                        
                            Metoprolol
                            Small molecule
                        
                        
                        
                            Losartan
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1491.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 2162.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.